Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer
structured guidance on exercise, protein, and long-term weight maintenance, that patients need but are not always receiving
In 2019, the United States Food and Drug Administration (FDA) documented adverse events in seven patients who received intravenous injections containing L-glutathione 200mg/mL compounded by a pharmacy using L-glutathione
They made it so easy and affordable
If your plan does not cover weight loss medications, we offer affordable alternatives through our compounding pharmacy partners at a fraction of the cost of brand-name options
The contrast is the whole point: clearance first, medical-grade product, blood-sugar and lab monitoring, and a provider who'll pull the plug if something looks off